Nymox Develops Powerful New Antibacterial for Chronic Urinary Infections.ROCKVILLE, MD--(BUSINESS WIRE)--Aug. 19, 1998--Nymox Pharmaceutical Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on National Market: NYMXF; Montreal Exchange Montreal Exchange A Canadian derivatives exchange that facilitates the trading of stock options, interest rate futures and options, as well as index options and futures. Located in Montreal, Quebec, it is the country's main financial derivative market, while the Winnipeg :NMX NMX Normas Mexicanas (non-mandatory Mexican standard) NMX Network Modular Extension ) announced today that the anti-infective program of Nymox's Pharmaceutical Division has made significant progress with its candidate NXB-4221, an antibacterial designed for the treatment of difficult chronic and persistent urinary tract infections. NXB-4221 has been shown to be highly effective against virulent bacteria in large studies of cultures from patients. NXB-4221 is targeted to treat acute and chronic urinary tract infections where currently available treatments are often inadequate in the elderly and in children, particularly in persons with spinal disorders and with chronic bladder catheterization catheterization Threading of a flexible tube (catheter) through a channel in the body to inject drugs or a contrast medium, measure and record flow and pressures, inspect structures, take samples, diagnose disorders, or clear blockages. . "We believe that NXB-4221 may fulfill a need in the problem area of recurrent infection, as well as in the acute treatment-resistant cases," said Paul Averback MD, President of Nymox. "This success in our anti-infective program is well on target for important clinical impact." NXB-4221 has thus far successfully completed several toxicity studies. Formulation and manufacturing protocols have been successfully established. NXB-4221 has demonstrated acceptable stability and a very good dose-response curve dose-response curve A graphic representation of the effects that varous doses of an agent–eg, ionizing radiation or a chemotherapeutic agent, have on a given parameter–eg, cell viability, mutation frequency, DNA damage, tumor growth or metastasis or . "The pre-clinical studies of NXB-4221 have gone forward very smoothly," said Iraj Behesthi Ph.D., VP and Director of Nymox's Clinical Laboratory and of Product Development. "We expect NXB-4221 to be tested in humans within one year. Our collaborators and the clinical sites are already prepared to move ahead." Colin Bier bier n. 1. A stand on which a corpse or a coffin containing a corpse is placed before burial. 2. A coffin along with its stand: followed the bier to the cemetery. Ph.D., Nymox's Director of Regulatory Affairs, said, "The activity and novelty of NXB-4221 are thus far such that we anticipate a timely IND submission." "The preparations for the NXB-4221 trials in the leading medical centers with which we are working are nicely on target," said Hossein Ghanbari Ph.D., Nymox's Senior Vice President for Research and Development and Strategic Planning. "This breakthrough is the achievement of a diversification program in our Diagnostic and Pharmaceutical Divisions." This press release contains certain "forward-looking statements", as defined in the United States Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. CONTACT: Nymox Corporation, Rockville Michael Munzar, M.D. Medical Director (800) 93NYMOX or NYMXF's INVESTOR RELATIONS Investor relations The process by which the corporation communicates with its investors. COUNSEL: The Equity Group, New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of Devin Sullivan (212) 836-9608 Ethan Denkensohn (212) 836-9611 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion